|1.||Frankel, Arthur E: 27 articles (01/2013 - 01/2002)|
|2.||Hochberg, Abraham: 12 articles (06/2014 - 03/2005)|
|3.||Vallera, Daniel A: 9 articles (09/2013 - 02/2002)|
|4.||Frankel, A E: 9 articles (02/2009 - 04/2000)|
|5.||Sing, Andreas: 7 articles (01/2015 - 06/2002)|
|6.||Hall, Walter A: 7 articles (09/2013 - 04/2002)|
|7.||Thorburn, Andrew: 7 articles (01/2013 - 11/2002)|
|8.||Kreitman, Robert J: 7 articles (01/2009 - 05/2002)|
|9.||Ohana, Patricia: 6 articles (01/2013 - 03/2005)|
|10.||Birman, Tatiana: 6 articles (01/2012 - 03/2005)|
01/01/2014 - "In addition, depletion of Foxp3+ cells using diphtheria toxin in Foxp3DTR mice reduced the frequency of type-2 macrophages (M2) in kidney tumors. "
02/01/2012 - "Our previous in vitro studies demonstrated that a construct comprised Rad51 promoter driving expression of the diphtheria toxin A gene (pRad51-diphtheria toxin A (DTA)) destroys a variety of human cancer cell lines, with minimal to no toxicity to normal human cells. "
04/15/2014 - "A construct containing Rad51C promoter driving diphtheria toxin A efficiently killed several types of cancer cells with very mild effect to normal cells. "
01/07/2013 - "Using our laboratory newly identified peptide TMTP1 and diphtheria toxin, we developed a new fusion protein that showed remarkable ability to target highly metastatic tumors. "
01/01/2013 - "Thus, a double promoter DTA-expressing vector was created, carrying on a single construct two separate genes expressing the diphtheria toxin a-fragment (DTA), from two different regulatory sequences, selected from the cancer-specific promoters IGF2-P4 and IGF2-P3. "
01/01/2010 - "Relatively low doses of EDA provided relatively high level of protection against diphtheria toxin that should be taken into account during treatment of diphtheria patients."
07/01/2009 - "The aim of this study was to examine the influence of diphtheria toxin B subunit on viability of diphtheria-sensitive cells using B subunit recombinant analogues. "
08/01/1994 - "The purpose of this study was to evaluate the immunity of Israeli adults against the diphtheria toxin and to assess the immune response to a 2 Lf booster vaccination of diphtheria. "
09/01/2015 - "ulcerans) produces the diphtheria toxin, which causes pharyngeal and cutaneous diphtheria-like disease in people, and this bacterium is commonly detected in dogs and cats that are reared at home. "
12/01/2014 - "ulcerans for the first time, we show that related sequence types (STs) might be associated with the presence of the diphtheria toxin gene, which encodes diphtheria toxin (DT), the most important diphtheria-causing virulence factor. "
|3.||Glioblastoma (Glioblastoma Multiforme)
01/01/2012 - "Transcriptional targeting of glioblastoma by diphtheria toxin-A driven by both H19 and IGF2-P4 promoters."
11/01/2009 - "EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins."
04/15/2003 - "A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells."
05/01/2002 - "Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice."
01/01/2009 - "We have exposed glioblastoma multiforme cells, such as U-251 MG, U-373 MG, SNB-19, and A-172 MG, to either anoxia or hypoxia and then reoxygenated them while treating with an interleukin (IL)-13-based diphtheria toxin (DT)-containing cytotoxin, DT-IL13QM. "
04/19/1989 - "A single ip or iv dose of 1-3 micrograms of diphtheria toxin consistently cured athymic mice of an advanced stage experimental human malignant mesothelioma. "
04/19/1989 - "Cure of experimental human malignant mesothelioma in athymic mice by diphtheria toxin."
05/01/2003 - "In addition, a diphtheria toxin-VEGF fusion protein (DT-VEGF), which is toxic to cells that express VEGF receptors was very effective in inhibiting mesothelioma cell growth in vitro. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/19/2014 - "Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein."
03/01/2008 - "DT(388)IL3 fusion protein containing the catalytic and translocation domains of diphtheria toxin fused to human interleukin 3 was administered in an inter-patient dose escalation trial by 15 min i.v. infusions every other day for up to 6 doses to patients with chemo-refractory acute myeloid leukemia (AML) and myelodysplasia (MDS). "
03/01/2008 - "Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia."
11/01/2002 - "In previous studies, we demonstrated that the diphtheria toxin-urokinase fusion protein DTAT was selectively toxic to acute myeloid leukemia (AML) cell lines overexpressing the CD87 urokinase receptor. "
05/01/2002 - "Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia."
|2.||denileukin diftitox (Ontak)
|3.||Proteins (Proteins, Gene)
|4.||Interleukin-2 Receptors (IL 2 Receptor)
|6.||DNA (Deoxyribonucleic Acid)
|9.||Transferrin (beta 2 Transferrin)
|10.||A-Form DNA (A-DNA)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)